Turn patient and HCP feedback into launch-ready evidence

Anonymous patient and healthcare professional surveys combined with expert-led insight generation for real-world data, pharmaceutical launch strategy, market access and clinical or medical decision-making.

Patients

lived experience

Healthcare professionals

clinical perspective

Actionable insights

clear strategic implications

From raw feedback to actionable patient and HCP insights

Novellas Healthcare combines survey design, healthcare access, compliant data collection and strategic interpretation in one practical model.

1. Survey design

Purpose built questions using plain language,
clear business objectives and predefined safety rules.

2. Patient & HCP reach

Relevant audiences are reached through groups,
platforms and trusted communities.

3. Anonymous collection

Feedback is collected using an approach designed
around anonymity and aggregated reporting.

4. Analysis & recommendations

Quantitative patterns, themes and controlled free text are translated
into a coherent insight narrative.
Insights are then translated into practical implications
for launch, access, medical and/or commercial teams.

Outputs are aggregated, anonymised and translated into strategic implications, not simply delivered as survey charts.

What pharmaceutical teams receive

Insight assets built for decision-making, internal alignment and practical activation.

Insight report

Key findings, visualised results,
aggregated quotes after redaction
and strategic implications.

Executive storyline

A concise narrative that leadership and cross-functional teams
can understand and use quickly.

Activation workshop

A facilitated session to translate findings into launch,
market access or medical actions.

Optional insights tracker

Repeatable survey waves to monitor changes
in awareness, barriers or behaviour over time.

Designed to reassure compliance, DPO and medical teams

The approach is designed around anonymous, aggregated insights with safeguards before collection and before sponsor reporting.

✅ Genuinely anonymous collection

No names, emails, IP addresses, account IDs or indirect identifiers are collected

✅ Aggregated sponsor output

Sponsors receive analysed insights rather than identifiable patient-level datasets.

✅ Group or platform reach-out

Patients can be reached via relevant communities or platforms rather than individual direct targeting.

✅ Configuration evidence

Relevant collection settings can be documented to demonstrate the configured anonymous approach.

What can patient and HCP insight research help answer?

  • Which patient barriers reduce uptake, adherence or engagement?
  • Which HCP beliefs influence referral, education or follow-up?
  • Which messages resonate, confuse or create objections?
  • Where does the care pathway create friction?
  • What should change in launch, market access, campaign or medical planning?

Patient & HCP insights: frequently asked questions

What are patient and HCP insights

Patient and HCP insights combine feedback from patients and healthcare professionals to better understand real-world behaviours, barriers, beliefs, unmet needs and care pathways. These insights can support pharmaceutical launch planning, market access, medical strategy, marketing and clinical projects.

How can patient insights support a pharmaceutical product launch?

Patient insight research can help identify awareness gaps, treatment barriers, education needs, care journey friction and real-world language before or during a pharmaceutical launch. Findings can then be translated into practical launch recommendations.

How can HCP insights improve launch and medical strategy?

HCP insights can help teams understand referral dynamics, clinical perceptions, education needs, objections and follow-up behaviour. This context can complement quantitative data and strengthen launch, access and medical planning.

Can patient and HCP surveys be anonymous?

Yes. The Novellas model described here is designed around anonymous collection and aggregated sponsor reporting, with safeguards intended to limit the collection of identifiable information.

What does a pharmaceutical company receive after an insight project?

Typical outputs can include an insight report, executive storyline, strategic recommendations, aggregated and redacted feedback, an activation workshop and, where appropriate, repeatable tracking waves.

Can insights be used to enrich real-world data?

Patient and HCP feedback can provide contextual information around observed behaviours, treatment pathways, barriers and unmet needs. This qualitative and quantitative context can complement real-world data when teams need to better understand why observed behaviours occur.

Start with one question worth answering.

A focused pilot can start by defining the target audience, business question, survey guardrails, expected timeline and deliverables.

    terms and conditions.